LimFlow has developed a revolutionary way of treating patients at risk of amputation.
Critical Limb Ischemia (CLI) is a complication of Peripheral Vascular Disease, a very frequent consequence of diabetes. It is characterized by profound, chronic pain, as well as extensive tissue loss that restricts revascularization options and frequently leads to amputation. CLI is estimated to have a fast growing incidence of approximately 50 to 100 per 100,000 per year, and is associated with mortality rates as high as 20% at 6 months after onset. Once ulcers appear on the patient's feet, it is very difficult to reverse the condition, and there is no alternative but amputation in a relatively short time frame.
The novel LimFlow approach to treating CLI employs the concept of venous arterialization (creating a shunt between an artery and a vein to restore blood flow to the foot through a vein, despite a clogged artery). Venous arterialization has been performed surgically for many years, with the first clinical surgical cases reported in the early twentieth century. However, it is deeply invasive and has not been widely adopted.
LimFlow has developed the world's first system for creating a percutaneous venous arterialization of the foot for the treatment of End Stage CLI. This is the first ever fully-endovascular approach to achieving venous arterialization of the leg : through small incisions in the foot and above the knee, catheter-based devices are threaded down the blood vessels in order to recreate a conduit for the blood to reach the foot of the patient. The LimFlow products have already been used to treat patients in the frame of clinical studies in Singapore, and in Europe.. CE mark was obtained in 2016.